J Neurol Surg B Skull Base 2024; 85(S 01): S1-S398
DOI: 10.1055/s-0044-1780287
Presentation Abstracts
Poster Abstracts

Secondary Malignancies in Patients with Pituitary Adenoma: A Surveillance, Epidemiology, and End Results (SEER) Data Analysis

Authors

  • Maxwell W. Pickles

    1   Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States

  • Thomas Z. Rohan

    1   Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States

  • David P. Bray

    2   Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, United States

  • James J. Evans

    2   Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Further Information
Also available at
 

Background: Pituitary adenoma is a frequently encountered intracranial mass that is typically characterized by slow growth and benign behavior. There remains limited knowledge regarding the risk of developing a “secondary malignancy” (SM) in a patient with a pituitary adenoma. This study assessed the risk of developing a SM after a pituitary adenoma diagnosis.

Methods: The Surveillance, Epidemiology, and End Results (SEER-17) data registry, which consisted of 9,208,295 patients, was utilized to generate a cohort of 60,677 patients diagnosed with pituitary adenoma to identify patients at risk for a SM. The SEER patient data were collected from the years 2000 to 2020. Statistical analysis was performed through SEER’s stat package and standardized incidence ratios (SIRs) for various malignancies after the diagnosis of primary meningioma were obtained. We also collected basic demographic, surgical, and postoperative data.

Results: Of the 60,677 patients, 4,067 (6.7%) received a diagnosis of a SM, which correlates to a higher risk than the general population (SIR, 1.1, 99% CI, 1.06–1.15). Patients with a pituitary adenoma had an increased risk of the following cancers: lymphatic and hematopoietic (SIR, 1.25; 99% CI, 1.09–1.41), kidney and renal pelvis (SIR, 1.45; 99% CI, 1.2–1.74), cutaneous melanoma (SIR, 1.36; 99% CI, 1.15–1.16), and thyroid cancer (SIR, 2.76; 99% CI, 2.32–3.26). Additionally, females were more predisposed to the following cancers: digestive system (SIR, 1.19; 99% CI, 1.11–1.25), and non-Hodgkin’s lymphoma (SIR, 1.41; 99% CI, 1.04–1.88).

Conclusion: Utilizing the SEER database, we displayed an increased risk of SM in patients with pituitary adenoma. Supplementary research may be done to determine any shared genetic abnormalities between the development of pituitary adenoma and these SMs. Additionally, further research of the endocrinological effects of pituitary adenoma and potential associations to SMs should be studied ([Fig. 1]; [Tables 1] and [2]).

Zoom
Zoom
Zoom


Publication History

Article published online:
05 February 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany